Abstract: The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof wherein “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1; and “r” is comprised from 1 to 10; a linker biradical of formula (II), which is connecting an alpha carbon atom of an amino acid located at position “i” in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence of formula (I); a C-terminal end corresponding to —C(O)R4; and a N-terminal end corresponding to —NHR5. The peptides of the invention show anticancer activity and an appropriate half-life and stability. Formula (I).

Abstract: The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof wherein “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1; and “r” is comprised from 1 to 10; a linker birradical of formula (II), which is connecting an alpha carbon atom of an amino acid located at position “i” in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence of formula (I); a C-terminal end corresponding to —C(O)R4; and a N-terminal end corresponding to —NHR5. Alternatively, the present invention provides a peptide or a pharmaceutical salt thereof which has an amino acid sequence with an identity from 85% to 95% with respect to sequence SEQ ID NO: 9: The peptides of the invention show anticancer activity.

Abstract: The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.

Abstract: The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.